NextCell Pharma AB’s rights issue heavily oversubscribed
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The demand was high and the Rights Issue was oversubscribed. Thus, no guarantees have been utilized. Through the Rights Issue, the Company receives approximately SEK 25.1 million before transaction costs.
- 4,111,192 shares were subscribed using subscription rights
- In addition, applications for subscription without using subscription rights corresponding to 11,750,102 shares have been received
- The Rights Issue was fully guaranteed through subscription undertakings of approximately SEK 8.4 million and guarantee commitments of approximately SEK 16.7 million
- No guarantee commitments have been utilized
The result in the Rights Issue shows that 4,111,192 shares were subscribed using subscription rights. The remaining part was subscribed without using subscription rights. The interest in subscription of shares without using subscription rights corresponded to 11,750,102 shares.
“We would like to thank everyone who participated in the issue. It is gratifying to note that there is a great interest in NextCell that resulted in a substantial oversubscription. The funds raised now enable Nextcell's continued development and we look forward to the company's upcoming listing on Nasdaq First North as well as to the implementation of planned projects, "says Anders Essen-Möller, Chairman of the Board.
Allocation of shares subscribed without using subscription rights within the Rights Issue has been done in accordance with the principles stated in the prospectus published on 3 June 2020. Notice of allotment is made through a settlement note sent to the respective subscribers. Payment for allotted shares must be made in accordance with the instructions in the settlement note.
Following registration of the new shares with the Swedish Companies Registration Office, the Company's share capital will increase by SEK 872,119.61 to a total of SEK 4,796,658.47. The number of shares in the Company will increase by 4,254,242 shares to a total of 23,398,334 shares.
Trading in paid subscribed shares (BTA) takes place on the Spotlight Stock Market until the new shares have been registered with the Swedish Companies Registration Office, which is expected to take place during week 28, 2020. As previously communicated, the Company has obtained conditional approval from Nasdaq, including customary reservations, regarding admission to trading of the Company’s shares on Nasdaq First North Growth Market. The list change is planned to take place in July.
Advisors
Vator Securities AB is financial advisor, and Eversheds Sutherland Advokatbyrå is legal advisor to NextCell in connection with the Rights Issue. Avanza Bank AB is issuing agent in connection with the Rights Issue. This information is such information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 24 June 2020.
Important information
The information in this press release does not constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in NextCell.
Neither subscription rights, paid subscribed shares ("BTA") nor newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTAs or newly issued shares have been registered or will be registered under the United States Securities Act of 1933 in its current wording, or under any other applicable law in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is contrary to applicable laws or regulations or requires that further prospectuses be prepared, registered or that any other measure is taken in addition to what is required by Swedish law. Accordingly, the press release, as well as the prospectus, application form and other documents attributable to the Rights Issue may not be distributed to or within any such jurisdiction.
This press release may contain some forward-looking information that reflects NextCell's current outlook on future events, as well as financial and operational development. Such words are e.g. "intended", "will", "assessed", "expected", "can", "plan", "estimate" and other expressions that imply indications or predictions regarding future developments or trends constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties, as it is dependent on future events and circumstances. Forward-looking information does not constitute a guarantee regarding future results or development and actual results may differ materially from what is stated in forward-looking information.
This information, the opinions and the forward-looking statements contained in this press release are valid only at this date and are subject to change without notice. NextCell Pharma AB makes no commitment to publish updates or revisions of forward-looking information, future events or similar circumstances other than as provided by applicable law.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB:
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
Tags: